The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial launch generated significant gains, the lapse of its intellectual property protection opened the floodgates to off-brand https://mediasocially.com/story6611170/the-copyright-and-the-pharmaceutical-industry-a-precarious-investment